论文部分内容阅读
EGFR表达异常见于多种恶性肿瘤,与肿瘤的生物学行为以及患者的预后有着密切联系。本文就EGFR基因突变在非小细胞肺癌(NSCLC)中的发生机制和分子靶向治疗的情况作一综述。一、EGFR基因突变EGFR为erbB家族成员之一,具有酪氨酸激酶活性,与HER2、HER3及HER4一起组成erbB家族。EGFR是一种跨膜糖蛋白受体,具有酪氨酸激酶活性,过度表达于45%～70
Abnormal EGFR expression is found in a variety of malignant tumors and is closely related to the biological behavior of the tumor and the prognosis of patients. This article reviews the pathogenesis of EGFR mutations in non-small cell lung cancer (NSCLC) and the molecular targeted therapy. EGFR gene mutation EGFR is one of the members of erbB family with tyrosine kinase activity and forms erbB family together with HER2, HER3 and HER4. EGFR is a transmembrane glycoprotein receptor with tyrosine kinase activity overexpressed in 45% to 70